AVO Aveon Group LP Com USD0.01

Advanced Medical Optics' ReZoom Lens to Benefit Cataract Patients Under New CMS Ruling on Presbyopic IOLs SANTA ANA, Calif., May 11 /PRNewswire-FirstCall/ -- Advanced Medical Optics, (AMO) (NYSE:AVO) a global leader in ophthalmic surgical devices and eye care products, announced today that the Centers for Medicare and Medicaid Services (CMS) ruled that Medicare beneficiaries may choose to receive presbyopia-correcting intraocular lenses (IOLs) for an additional fee as part of cataract surgery. These lenses, including AMO's ReZoom(TM) multifocal IOL, provide vision for distance, intermediate and near ranges. (Logo: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO) AMO pioneered the concept of an IOL that provides distance, intermediate and near vision in the late 1990s when it received the first-ever FDA approval for a multifocal lens. In March 2005, AMO received FDA approval for its second-generation multifocal technology, the ReZoom(TM) IOL. In a 215-patient European study, 93 percent of ReZoom(TM) patients reported never or only occasionally having to wear glasses. "This provides an important new opportunity for Medicare cataract patients to enjoy a full range of distance, intermediate and near vision after surgery," said Jim Mazzo, president and CEO of AMO." The ReZoom(TM) IOL features Balanced View Optics(TM) technology that distributes light over five optic zones for enhanced restoration of visual function for reduced spectacle dependence. This allows the ReZoom(TM) IOL to match its performance characteristics with the lifestyle demands of the patients. About Advanced Medical Optics (AMO) AMO is a global leader in the development, manufacturing and marketing of ophthalmic surgical and eye care products. The company focuses on developing a broad suite of innovative technologies and devices to address a wide range of eye disorders. Products in the ophthalmic surgical line include intraocular lenses, phacoemulsification systems, viscoelastics, microkeratomes and related products used in cataract and refractive surgery. AMO owns or has the rights to such ophthalmic surgical product brands as ReZoom(TM), Phacoflex(R), Clariflex(R), Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM) intraocular lenses, Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) and Amadeus(TM) II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the contact lens care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the contact lens care product brands the company possesses are COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R) and blink(TM) branded products. Amadeus is a licensed product of, and a trademark of, SIS, Ltd. OptiEdge(TM) is a registered trademark of Ocular Sciences. AMO is based in Santa Ana, California, and employs approximately 3,000 worldwide. The company has operations in about 20 countries and markets products in approximately 60 countries. For more information, visit the company's Web site at http://www.amo-inc.com/. Forward-Looking Statements This press release contains forward-looking statements about AMO and its business such as Mr. Mazzo's statements and statements about AMO's sales of ReZoom(TM) IOL. Any statements in this press release that refer to AMO's estimated or anticipated future results are forward-looking statements. All forward-looking statements in this press release reflect AMO's current analysis of existing trends and information and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors affecting AMO's business, including risks of technology development failures and product feasibility; the execution of strategic initiatives; the uncertainties associated with intellectual property protection for these products; and the actual benefit, implementation and modification of the CMS ruling. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous financial press releases issued by AMO. AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting AMO and its Businesses" in AMO's 2005 Form 10-Q filed in April 2005 include information concerning these and other risk factors. Copies of press releases and additional information about AMO are available at http://www.amo-inc.com/, or you can contact the AMO Investor Relations Department by calling 714-247-8348. Advanced Medical Optics, Inc. Investors: Sheree Aronson (714) 247-8290 Media: Steve Chesterman (714) 247-8711 http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO http://photoarchive.ap.org/ DATASOURCE: Advanced Medical Optics CONTACT: investors, Sheree Aronson, +1-714-247-8290, , or media, Steve Chesterman, +1-714-247-8711, , both of Advanced Medical Optics Web site: http://www.amo-inc.com/

Copyright